• Selective P2X1 Receptor Inhibition Modulates Platelet Thromb

  2026-08-03

  This study establishes NF449 as a highly selective antagonist of the platelet P2X1 receptor, demonstrating its ability to dissect the distinct roles of P2X1, P2Y1, and P2Y12 in platelet activation and thrombus formation. The findings clarify purinergic signaling in platelets and suggest new antithrombotic strategies with improved safety profiles.

• Applied Protocols for MK-4827 (Niraparib) in Cancer Research

  2026-08-03

  MK-4827 (Niraparib) unlocks powerful DNA damage repair inhibition in BRCA-mutant and spliceosome-targeted cancer models, driving both stand-alone and combination protocols. This article delivers stepwise workflow guidance, highlights troubleshooting tactics, and translates new findings on spliceosome modulation into actionable research strategies.

• K+ Channel Blockade Alters Renal Response to Norepinephrine

  2026-08-02

  This study investigates how different potassium channel blockers influence renal blood flow responses to norepinephrine and phenylephrine in septic rats. The findings reveal that blocking specific K+ channel subtypes can exacerbate renal hypoperfusion when combined with vasoconstrictors, highlighting a critical interplay between vascular ion channel function and adrenergic signaling during sepsis.

• GPR35-KLF5 Circuitry Orchestrates Colonic Epithelial Repair

  2026-08-01

  The referenced study reveals how intestinal epithelial cells decode mucosal damage through a tryptophan metabolism-sensing GPR35-KLF5 circuit, orchestrating repair responses in ulcerative colitis models. This mechanistic insight advances understanding of barrier restitution after injury and provides a potential therapeutic target for inflammatory bowel disease.

• Hyperthermia Enhances PARP Inhibitor Sensitivity in BRCA2-Pr

  2026-07-31

  Mei et al. reveal that hyperthermia reduces BRCA2 protein levels, sensitizing BRCA2-proficient ovarian carcinoma cells to PARP inhibition. This finding provides a mechanistically rational approach for overcoming intrinsic PARP inhibitor resistance in BRCA2-intact tumors and supports combination strategies in preclinical models.

• 3D Gold Nanocluster Arrays via Polymer Pen Lithography for S

  2026-07-31

  The reference study pioneers a scalable, programmable strategy for fabricating highly ordered three-dimensional gold nanocluster arrays using polymer pen lithography. By enabling precise control over substrate geometry, this approach delivers exceptional SERS sensitivity and reproducibility, advancing the utility of SERS in biosensing and analytical applications.

• CA-074 Me: Precision Cathepsin B Inhibitor for Lysosomal Res

  2026-07-30

  CA-074 Me empowers researchers to dissect lysosomal protease-driven cell death with high selectivity and workflow flexibility. Its potency and membrane permeability make it indispensable for apoptosis, necroptosis, and inflammation studies demanding reliable cathepsin B inhibition.

• Phenytoin and AEDs Inhibit Human Serum PON1: Mechanistic Ins

  2026-07-30

  This study systematically explores the inhibitory effects of phenytoin and other antiepileptic drugs on human serum paraoxonase-1 (hPON1) in vitro, revealing noncompetitive inhibition kinetics. These findings highlight a potential mechanistic link between antiepileptic drug therapy and altered lipid metabolism, with important implications for the design of sodium channel modulation and neurological disease research.

• Retinoic Acid Overcomes PARP Inhibitor Resistance in Ovarian

  2026-07-29

  This study demonstrates that all-trans retinoic acid (ATRA) can reverse cisplatin-induced resistance to PARP inhibitors, including Niraparib (MK-4827), in epithelial ovarian cancer models. The findings highlight a promising combinatorial approach for overcoming therapeutic resistance and improving maintenance strategies in both BRCA-mutant and wild-type ovarian cancers.

• NHS-Biotin in Multimeric Protein Engineering: Mechanism, Pro

  2026-07-29

  Discover how NHS-Biotin enables precise biotinylation of antibodies and proteins for advanced multimeric protein engineering. This in-depth guide goes beyond protocol basics, dissecting mechanistic foundations and extracting practical innovations from recent research.

• Network Pharmacology Reveals SFI's Anti-Glioma Mechanism via

  2026-07-28

  This study employs network pharmacology and experimental validation to elucidate how Shenqi Fuzheng injection (SFI) inhibits glioma cell proliferation and migration, primarily through the SRC/PI3K/AKT signaling pathway. The findings clarify SFI’s multi-target anti-glioma effects, providing molecular insights with implications for anti-angiogenic and tumor inhibition research.

• Live-Dead Cell Staining Kit: Reliable Dual-Fluorescence Work

  2026-07-28

  This scenario-driven guide explores how the Live-Dead Cell Staining Kit (SKU K2081) from APExBIO addresses core challenges in cell viability and cytotoxicity assays. Drawing from real-world laboratory needs, it demonstrates reliable Calcein-AM Propidium Iodide staining for reproducible, quantitative results in advanced biomedical research.

• Palmitic acid (Hexadecanoic Acid): Technical Use and Protoco

  2026-07-27

  Palmitic acid (SKU N2456) provides a high-purity, well-characterized saturated long-chain fatty acid for research applications requiring precise control over lipid supplementation, such as studies of protein palmitoylation, lipid metabolism, and metabolic disorder pathways. This product is not suitable for protocols requiring aqueous solubility or long-term solution storage, making accurate handling and immediate use essential for reliable results.

• Thiazovivin for Stem Cell Research: Protocols and Best Pract

  2026-07-27

  Thiazovivin is a high-purity ROCK inhibitor optimized for enhancing fibroblast reprogramming and improving human embryonic stem cell survival, particularly during induced pluripotent stem cell generation. It is strictly intended for controlled research workflows and should not be used in diagnostic or therapeutic applications.

• Deferiprone: Iron Chelation, Apoptosis Induction, and Resear

  2026-07-26

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is a selective iron chelator widely used to modulate iron-dependent cellular pathways in cancer and metabolic research. It induces apoptosis via iron depletion and protects against doxorubicin-induced cytotoxicity. Its solubility profile and proven efficacy make it a benchmark tool for dissecting iron-mediated mechanisms in vitro and in vivo.

16780 records 1/1119 page Next 12345 下5页 Last page